cas 2799-21-5|| where to buy (R)-3-Pyrrolidinol

製品名:(R)-3-Pyrrolidinol

IUPAC Name:(3R)-pyrrolidin-3-ol

包装単位	有効在庫	価格（USD）
CM116633-25g	in stock	ǆŸ
CM116633-100g	in stock	şƚǆ
CM116633-500g	in stock	Ɛƚǆ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2799-21-5 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:2799-21-5; 分子式:C4H9NO; 融点:-; SMILESコード:O[C@H]1CNCC1; 密度:

: カタログ番号:CM116633; 分子量:87.12; 沸点:224.7°C at 760 mmHg; MDL番号:MFCD00145220; 保管方法:Keep in dark place, inert atmosphere, store at 2-8°C.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.

: Asciminib; Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.